false 0001642159 0001642159 2024-06-06 2024-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): June 6, 2024 (May 30, 2024)

 

SIGYN THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   333-204486   47-2573116

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

2468 Historic Decatur Road    
Suite 140    
San Diego, California   92106
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 619.368.2000

 

Prior address and phone number:

 

2468 Historic Decatur Road, Suite 140    
San Diego, CA   92106
(Address of principal executive offices)   (Zip Code)

 

619.353.0800

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events

 

From May 30, 2024 through June 6, 2024, the holders of $226,903 of Original Issue Discount Senior Convertible Debentures elected to convert their debentures at an average contractual exercise price of $6.00 per share in exchange for the issuance of 37,820 shares of the Company’s Common Stock to the holders.

 

As a result of these issuances, the number of outstanding common shares of the Company has increased from 1,225,833 to 1,263,653.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SIGYN THERAPEUTICS, INC.
     
Date: June 6, 2024 By: /s/ James A. Joyce
    James A. Joyce, Chairman and CEO

 

 

v3.24.1.1.u2
Cover
Jun. 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 06, 2024
Entity File Number 333-204486
Entity Registrant Name SIGYN THERAPEUTICS, INC.
Entity Central Index Key 0001642159
Entity Tax Identification Number 47-2573116
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2468 Historic Decatur Road
Entity Address, Address Line Two Suite 140
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92106
City Area Code 619
Local Phone Number 353.0800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Grafico Azioni Sigyn Therapeutics (QB) (USOTC:SIGYD)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Sigyn Therapeutics (QB)
Grafico Azioni Sigyn Therapeutics (QB) (USOTC:SIGYD)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Sigyn Therapeutics (QB)